ZA968087B - Truncated glial cell line-derived neurotrophic factor - Google Patents

Truncated glial cell line-derived neurotrophic factor

Info

Publication number
ZA968087B
ZA968087B ZA968087A ZA968087A ZA968087B ZA 968087 B ZA968087 B ZA 968087B ZA 968087 A ZA968087 A ZA 968087A ZA 968087 A ZA968087 A ZA 968087A ZA 968087 B ZA968087 B ZA 968087B
Authority
ZA
South Africa
Prior art keywords
cell line
neurotrophic factor
derived neurotrophic
glial cell
truncated
Prior art date
Application number
ZA968087A
Other languages
English (en)
Inventor
Shaw-Fen Sylvia Hu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA968087B publication Critical patent/ZA968087B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA968087A 1995-09-28 1996-09-26 Truncated glial cell line-derived neurotrophic factor ZA968087B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/535,681 US6184200B1 (en) 1995-09-28 1995-09-28 Truncated glial cell line-derived neurotrophic factor

Publications (1)

Publication Number Publication Date
ZA968087B true ZA968087B (en) 1997-06-12

Family

ID=24135310

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968087A ZA968087B (en) 1995-09-28 1996-09-26 Truncated glial cell line-derived neurotrophic factor

Country Status (25)

Country Link
US (5) US6184200B1 (xx)
EP (1) EP0920448B1 (xx)
JP (3) JP4153036B2 (xx)
KR (1) KR100334739B1 (xx)
CN (1) CN1283659C (xx)
AT (1) ATE314389T1 (xx)
AU (1) AU707528B2 (xx)
CA (1) CA2232749C (xx)
CZ (1) CZ297326B6 (xx)
DE (1) DE69635675T2 (xx)
DK (1) DK0920448T3 (xx)
EA (1) EA001204B1 (xx)
ES (1) ES2255713T3 (xx)
HK (1) HK1021823A1 (xx)
HU (1) HU226220B1 (xx)
IL (6) IL144488A0 (xx)
MX (1) MX9802278A (xx)
NO (1) NO322521B1 (xx)
NZ (1) NZ318697A (xx)
SI (1) SI0920448T1 (xx)
SK (1) SK288094B6 (xx)
TW (1) TW570926B (xx)
UA (1) UA66339C2 (xx)
WO (1) WO1997011964A1 (xx)
ZA (1) ZA968087B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6507788B1 (en) * 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US6897061B1 (en) 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7245117B1 (en) 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
KR101304081B1 (ko) * 2006-08-04 2013-09-05 프로롱 파마슈티컬스, 엘엘씨 수식된 에리스로포이에틴
US20090069230A1 (en) * 2007-02-12 2009-03-12 The Research Foundation Of State University Of New York Gdnf-derived peptides
US8329655B2 (en) 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
US8446454B2 (en) 2007-05-21 2013-05-21 Polycom, Inc. Dynamic adaption of a continuous presence videoconferencing layout based on video content
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
UA112981C2 (uk) 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
EP2968462B1 (en) 2013-03-15 2020-12-23 The Jackson Laboratory Methods for promoting wound healing and hair growth
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
EP3538560A4 (en) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. GDNF FUSION POLYPEPTIDES AND METHODS OF USE
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
CA1332433C (en) 1989-09-29 1994-10-11 Robert L. Sutherland Ski structure and binding therefor
DE69034258D1 (de) 1989-10-16 2008-09-18 Amgen Inc Stamzellfaktor
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US7226758B1 (en) 1991-09-20 2007-06-05 Amgen Inc. Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)
AU1443095A (en) 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
DK0920448T3 (da) 2006-04-10
IL123761A (en) 2005-12-18
KR19990063825A (ko) 1999-07-26
CN1197461A (zh) 1998-10-28
CZ297326B6 (cs) 2006-11-15
EA199800301A1 (ru) 1998-10-29
AU7074696A (en) 1997-04-17
NO981430L (no) 1998-03-30
IL218336A0 (en) 2012-04-30
WO1997011964A1 (en) 1997-04-03
US6184200B1 (en) 2001-02-06
CN1283659C (zh) 2006-11-08
CA2232749A1 (en) 1997-04-03
JP4909843B2 (ja) 2012-04-04
HUP9802262A2 (hu) 1999-01-28
MX9802278A (es) 1998-08-30
CA2232749C (en) 2003-03-25
NZ318697A (en) 1999-09-29
KR100334739B1 (ko) 2002-09-17
JP2010279360A (ja) 2010-12-16
DE69635675D1 (de) 2006-02-02
US20040254114A1 (en) 2004-12-16
US7611865B2 (en) 2009-11-03
IL144018A0 (en) 2002-04-21
DE69635675T2 (de) 2006-07-06
US20040214776A1 (en) 2004-10-28
JP2008067699A (ja) 2008-03-27
US20110251267A1 (en) 2011-10-13
US20040127419A1 (en) 2004-07-01
SK288094B6 (sk) 2013-07-02
AU707528B2 (en) 1999-07-15
HUP9802262A3 (en) 2001-01-29
CZ88298A3 (cs) 1999-02-17
EA001204B1 (ru) 2000-12-25
JP5241037B2 (ja) 2013-07-17
IL144488A (en) 2006-12-31
ATE314389T1 (de) 2006-01-15
HU226220B1 (hu) 2008-06-30
IL123761A0 (en) 1998-10-30
US7390781B2 (en) 2008-06-24
JPH11512709A (ja) 1999-11-02
JP4153036B2 (ja) 2008-09-17
SK38998A3 (en) 1999-07-12
NO981430D0 (no) 1998-03-30
EP0920448B1 (en) 2005-12-28
HK1021823A1 (en) 2000-07-07
IL144018A (en) 2012-04-30
ES2255713T3 (es) 2006-07-01
IL144488A0 (en) 2002-05-23
NO322521B1 (no) 2006-10-16
UA66339C2 (uk) 2004-05-17
SI0920448T1 (sl) 2006-04-30
EP0920448A1 (en) 1999-06-09
TW570926B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
IL218336A0 (en) Polynucleotides encoding truncated glial derived neurotrophic factors and methods of using said polynucleotides
IL148060A0 (en) Compositions and methods for improved cell culture
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
WO2002029083A3 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
GB9822576D0 (en) Membrane
AU7471698A (en) Intracellular production of hepatitis c e1 and e2 truncated polypeptides
DE69638077D1 (de) Bakterielle Produktion von Interferon-beta Polypeptiden
AU7659298A (en) Recombinant lactoferrin, methods of production from plants and uses
IL140937A0 (en) Molecules designated ldcam
HUP9902640A2 (hu) Gliasejtvonal-eredetű neurotróf faktor receptor
ES2193192T3 (es) Receptores de interleuquina-15.
ZA887773B (en) Interleukin-7
NZ234048A (en) Interleukin-7 (il-7) receptor and pharmaceutical compositions
AU1676302A (en) Alteration of cell membrane for new functions
EP0876095A4 (en) ELECTROPORATION OF MEDIATED MOLECULAR TRANSFER IN INTACT PLANTS
YU41798A (sh) Scf analogni preparati i postupci
AU8294991A (en) Protease resistant pdgf and methods of use
GB2322132B (en) Keratinocyte growth factor-2 products
CA2263790A1 (en) Method for immortalizing cells
IL154543A0 (en) The neurotrophic factor nnt-1